According to a new report, published by KBV research, The Global Myasthenia Gravis Treatment Market size is expected to reach $3.8 billion by 2030, rising at a market growth of 9.2% CAGR during the forecast period.
The Hospitals segment is registering maximum revenue in the Global Myasthenia Gravis Treatment Market by End-use in 2022; thereby, achieving a market value of $2,.1 billion by 2030. Hospitals, especially those with specialized neurology or neuromuscular departments, often serve as primary centers for the diagnosis and management of myasthenia gravis. They have the equipment and expertise to conduct specific tests and evaluations for accurate diagnosis. Severe cases of myasthenia gravis might require more intensive treatment, such as intravenous immunoglobulin or plasmapheresis.
The Cholinesterase Inhibitors segment is exhibiting a CAGR of 9.6% during (2023 - 2030). Cholinesterase inhibitors have been a mainstay in treating myasthenia gravis for many years. They are often the first-line pharmacological treatment, and their use is well-established in managing the condition's symptoms. While effective in many cases, cholinesterase inhibitors may not be as effective in managing severe forms of myasthenia gravis. Therefore, in more severe cases, they are often used with other immunosuppressive medications or newer therapeutic options.
The North America region is generating the highest revenue in the Global Myasthenia Gravis Treatment Market by Region in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $1.8 billion by 2030. The Europe region is experiencing a CAGR of 9% during (2023 - 2030). Additionally, The Asia Pacific region would exhibit a CAGR of 10.2% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/myasthenia-gravis-treatment-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of AstraZeneca PLC (Alexion Pharmaceuticals, Inc.), Octapharma AG, Novartis AG, Pfizer, Inc., Allergan PLC (AbbVie, Inc.), F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Bausch Health Companies Inc., Kedrion S.p.A, and Zydus Lifesciences Ltd.
By End-use
By Type
By Geography
Companies Profiled
Unique Offerings 
